|Bid||37.64 x 0|
|Ask||38.10 x 0|
|Day's Range||37.63 - 38.06|
|52 Week Range||27.70 - 41.06|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||24.14|
|Forward Dividend & Yield||0.96 (2.52%)|
|1y Target Est||N/A|
Q1 2019 Recordati Industria Chimica e Farmaceutica SpA Earnings & 2019-2021 Business Plan Call
Italian drugmaker Zambon is looking to China and the U.S. to grow its respiratory and nervous system portfolio and could spend more than 100 million euros ($114 million) on the right acquisition, its chief executive said. The family-owned pharma group, famous for its mucolytic agent Fluimucil, used to treat respiratory problems, has cash enough to fund expansion plans but could contemplate a stock market listing if a big opportunity arose. "It's not on the table at the moment, but we could consider it if a large-scale project comes along," Roberto Tascione told Reuters in an interview.
Dividends can be underrated but they form a large part of investment returns, playing an important role in compounding returns in the long run. Historically, Recordati Industria Chimica e Farmaceutica Read More...